Blog Exposure – Emergent BioSolutions and Profectus BioSciences Receive Contract from CEPI to Develop Nipah Virus Vaccine

Stock Monitor: Imprimis Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EBS as the Company’s latest news hit the wire. On May 24, 2018, the Company announced that the Coalition for Epidemic Preparedness Innovations (CEPI) has provided up to $25 million to the Company and Profectus BioSciences, Inc. (“Profectus”) to advance the development and manufacture of a vaccine against the Nipah virus (NiV), a bat-borne virus that can spread to both humans and livestock. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which also belongs to the Healthcare sector as the Company Emergent BioSolutions. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=IMMY

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Emergent BioSolutions most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=EBS

CEPI is an innovative partnership between public, private, philanthropic, and civil organizations founded in Davos, in 2017, to develop vaccines to stop future epidemics.

Terms of the Agreement

Profectus will receive development funding from CEPI for advancing its Nipah virus vaccine and Emergent will provide technical and manufacturing support for the CEPI-funded program.

Emergent, through a separate agreement with Profectus, has an exclusive option to license and to assume control of development activities for the Nipah virus vaccine from Profectus.

The international non-profit organization PATH will also be working with the consortium under a separate agreement with CEPI to work on clinical development.

The agreement will enable funding for development efforts over a five-year period.

Profectus will Apply its Technologies and Leverage its Partnership with Emergent to Advance the Pre-IND Vaccine Candidate for Nipah Virus

Thomas Lynch, Chairman and Chief Executive Officer (CEO) of Profectus, stated that the Company gratefully acknowledges CEPI’s leadership and funding of this strategic collaboration to rapidly produce a vaccine against the emerging Nipah virus threat. The Nipah virus’ human-to-human transmission has been documented, and any initially small outbreak could take the same course as the recent Ebola outbreak. Lynch added that with CEPI’s support and the talents of these highly regarded global health innovation partners, Profectus looks forward to applying its expertise and technologies, and leveraging its partnership with Emergent to rapidly advance the pre-IND vaccine candidate for the Nipah virus as an effective countermeasure that will be positioned to save patients around the world from this devastating disease.

Emergent to Leverage its US Government-Designated Center for Innovation in Advanced Development and Manufacturing

Daniel J. Abdun-Nabi, CEO of Emergent, stated that the Company has a 20-year track record of success working with government and industry partners to provide life-saving medical countermeasures against identified biological agents, particularly when a rapid response to an emerging outbreak may be necessary. Abdun-Nabi added that Emergent looks forward to leveraging its expertise in advanced development and manufacturing, including its US government-designated Center for Innovation in Advanced Development and Manufacturing, which is designed to provide surge manufacturing capabilities during public health emergencies.

About the Nipah Virus

The Nipah virus and the Hendra virus (HeV) are closely related Paramyxoviruses that cause respiratory and encephalitis diseases in a variety of animal hosts and in humans. A natural reservoir for these viruses are flying foxes found in Southeast Asia and Malaysia. Human infection occurs after direct exposure to tissues and secretions from infected horses, pigs, and bats. There is currently no approved vaccine or therapeutic against either NiV or HeV. The only treatment option for human cases is intensive supportive care. The Southern India state of Kerala is currently in the midst of a Nipah virus outbreak, where the virus has already killed 10 people. These are the first documented cases in Kerala.

About Emergent BioSolutions Inc.

Founded in 1998 and headquartered in Gaithersburg, Maryland, Emergent is a global life sciences organization dedicated to one simple mission: to protect and enhance life. The Company develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats, as well as emerging infectious diseases.

About Profectus BioSciences Inc.

Profectus is an innovative clinical stage vaccine organization devoted to preventing and treating viral diseases and malaria through the application of its proprietary pDNA and rVSV platform. The Company is headquartered in Baltimore, Maryland.

Stock Performance Snapshot

May 25, 2018 – At Friday’s closing bell, Emergent BioSolutions’ stock declined 1.23%, ending the trading session at $49.99.

Volume traded for the day: 130.69 thousand shares.

Stock performance in the last three-month – up 0.71%; previous six-month period – up 22.31%; past twelve-month period – up 65.53%; and year-to-date – up 7.57%

After last Friday’s close, Emergent BioSolutions’ market cap was at $2.52 billion.

Price to Earnings (P/E) ratio was at 37.73.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 501032